WO2015124764A8 - Synthesis process of dabigatran etexilate mesylate, intermediates of the process and novel polymorph of dabigatran etexilate - Google Patents
Synthesis process of dabigatran etexilate mesylate, intermediates of the process and novel polymorph of dabigatran etexilate Download PDFInfo
- Publication number
- WO2015124764A8 WO2015124764A8 PCT/EP2015/053702 EP2015053702W WO2015124764A8 WO 2015124764 A8 WO2015124764 A8 WO 2015124764A8 EP 2015053702 W EP2015053702 W EP 2015053702W WO 2015124764 A8 WO2015124764 A8 WO 2015124764A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dabigatran etexilate
- intermediates
- mesylate
- novel polymorph
- synthesis process
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
A novel process is described for the production of Dabigatran etexilate mesylate, a compound having the following structural formula and two novel intermediates of said process.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITMI20140272 | 2014-02-24 | ||
| ITMI2014A000272 | 2014-02-24 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2015124764A1 WO2015124764A1 (en) | 2015-08-27 |
| WO2015124764A8 true WO2015124764A8 (en) | 2015-12-30 |
Family
ID=50693778
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2015/053702 Ceased WO2015124764A1 (en) | 2014-02-24 | 2015-02-23 | Synthesis process of dabigatran etexilate mesylate, intermediates of the process and novel polymorph of dabigatran etexilate |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2015124764A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017037743A2 (en) * | 2015-09-03 | 2017-03-09 | Sun Pharmaceutical Industries Limited | Dabigatran etexilate 1,4-butanedisulfonate salt and its crystal form |
| CN105294651A (en) * | 2015-09-23 | 2016-02-03 | 烟台东诚药业集团股份有限公司 | Method for synthesizing and preparing pradaxa formamidine intermediates |
| CN105153118A (en) * | 2015-09-24 | 2015-12-16 | 青岛黄海制药有限责任公司 | Central control method of midbody in dabigatran etexilate mesylate preparation process |
| CN105906607A (en) * | 2015-12-23 | 2016-08-31 | 嘉实(湖南)医药科技有限公司 | Dabigatran etexilate synthesis method |
| CN108658939B (en) * | 2018-07-16 | 2021-07-20 | 上海现代制药股份有限公司 | A kind of synthetic method of key intermediate of dabigatran etexilate mesylate |
| CN115141124A (en) * | 2022-06-16 | 2022-10-04 | 重庆华森制药股份有限公司 | Method for preparing gabexate mesylate |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6087380A (en) | 1949-11-24 | 2000-07-11 | Boehringer Ingelheim Pharma Kg | Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions |
| DE102005020002A1 (en) | 2005-04-27 | 2006-11-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Physiologically acceptable salts of 3 - [(2 - {[4- (hexyloxycarbonylamino-imino-methyl) -phenyl-amino] -methyl} -1-methyl-1H-benzimidazole-5-carbonyl) -pyridin-2-yl-amino] - propionate |
| DE102005025728A1 (en) | 2005-06-04 | 2006-12-07 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Polymorphs of 3 - [(2 - {[4- (hexyloxycarbonylamino-imino-methyl) -phenyl-amino] -methyl} -1-methyl-1H-benzimidazole-5-carbonyl) -pyridin-2-yl-amino] -propionic acid ethyl ester |
| US20100087488A1 (en) | 2006-10-10 | 2010-04-08 | Boehringer Ingelheim International Gmgh | Physiologically Acceptable Salts of 3-[(2--1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester |
| DE102006054005A1 (en) | 2006-11-16 | 2008-05-21 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New polymorphs of 3 - [(2 - {[4- (hexyloxycarbonylamino-imino-methyl) -phenyl-amino] -methyl} -1-methyl-1H-benzimidazole-5-carbonyl) -pyridin-2-yl-amino] -propionic acid ethyl |
| CZ305085B6 (en) * | 2008-03-14 | 2015-04-29 | Zentiva, K.S. | Process for preparing dabigatran |
| EP2937343A1 (en) * | 2010-07-09 | 2015-10-28 | Esteve Química, S.A. | Process of preparing a thrombin specific inhibitor |
| WO2012027543A1 (en) | 2010-08-25 | 2012-03-01 | Teva Pharmaceuticals Usa, Inc. | Solid state forms of dabigatran etexilate, dabigatran etexilate mesylate and processes for preparation thereof |
| ES2550771T3 (en) | 2010-09-27 | 2015-11-12 | Ratiopharm Gmbh | Dabigatran bistexilate ethoxylate salt, solid state forms and process for preparing them |
| US9006448B2 (en) | 2010-12-06 | 2015-04-14 | Msn Laboratories Private Limited | Process for the preparation of benzimidazole derivatives and its salts |
| EP2522662A1 (en) * | 2011-05-11 | 2012-11-14 | Medichem, S.A. | Dabigatran etexilate and related substances, processes and compositions, and use of the substances as reference standards and markers |
| US9212166B2 (en) | 2012-01-20 | 2015-12-15 | Cadila Healthcare Limited | Process for the preparation of dabigatran etexilate mesylate and polymorphs of intermediates thereof |
| WO2013124749A1 (en) | 2012-02-20 | 2013-08-29 | Alembic Pharmaceuticals Limited | Novel polymorph of dabigatran etexilate |
| EP2631234A1 (en) | 2012-02-23 | 2013-08-28 | Esteve Química, S.A. | Solid forms of dabigatran etexilate mesylate and processes for their preparation |
| WO2013144903A1 (en) | 2012-03-28 | 2013-10-03 | Dr. Reddy's Laboratories Limited | Processes for the preparation of dabigatran etexilate |
| EP2834224B1 (en) * | 2012-04-02 | 2018-06-06 | MSN Laboratories Limited | Process for the preparation of benzimidazole derivatives and salts thereof |
-
2015
- 2015-02-23 WO PCT/EP2015/053702 patent/WO2015124764A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015124764A1 (en) | 2015-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2015195656A3 (en) | Synthesis of polycyclic-carbamoylpyridone compounds | |
| WO2015110897A3 (en) | Novel process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof | |
| WO2016011390A8 (en) | Irak4 inhibiting agents | |
| WO2016079751A3 (en) | A process for preparation of vortioxetine and polymorphs thereof | |
| WO2015008218A3 (en) | Process for the preparation of suvorexant and intermediates useful in the synthesis of suvorexant | |
| WO2015124764A8 (en) | Synthesis process of dabigatran etexilate mesylate, intermediates of the process and novel polymorph of dabigatran etexilate | |
| WO2015142903A3 (en) | Method of controlling lactate production with piperdine-dione derivatives | |
| WO2016071435A3 (en) | Synthesis of copanlisib and its dihydrochloride salt | |
| WO2018029711A3 (en) | Process for the preparation of venetoclax | |
| WO2013111163A3 (en) | Process for the preparation of dabigatran etexilate mesylate and polymorphs of intermediates thereof | |
| WO2014192030A3 (en) | An improved process for preparation of dabigatran etexilate and pharmaceutically acceptable acid addition salts thereof | |
| SG11202009623VA (en) | A compound, a reaction product of said compound and production methods thereof | |
| HK1246299A1 (en) | Process of making cenicriviroc and related analogs | |
| WO2018091964A8 (en) | Process for preparing methoxy methyl pyridine dicarboxylate | |
| WO2015128875A3 (en) | A process for preparation of dabigatran etexilate mesylate and intermediates thereof | |
| WO2015121877A3 (en) | Polymorphs of lomitapide and its salts | |
| IL274824A (en) | Polymorphs and solid forms of a pyrimidinylamino-pyrazole compound, and methods of production | |
| WO2016024286A3 (en) | An improved process for synthesis of lenalidomide | |
| WO2016108206A3 (en) | Processes for preparation of idelalisib and intermediates thereof | |
| WO2016024284A3 (en) | A process for the preparation of mirabegron and its intermediates | |
| MX2019001228A (en) | Production method for pyrazole-amide compound. | |
| ZA202101670B (en) | Process for the production of syngas | |
| WO2015181802A3 (en) | Oral pharmaceutical composition of isotretinoin | |
| WO2015191681A3 (en) | Substituted pyridinones as mgat2 inhibitors | |
| MX2016012485A (en) | Process of preparing 3-(3-(4-(1-aminocyclobutyl)phenyl)-5-phenyl- 3h-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15711432 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 15711432 Country of ref document: EP Kind code of ref document: A1 |